We utilized the human 4F2 heavy-chain (4F2HC) gene as a model system to study the regulation of inducible gene expression during normal human T-cell activation. Previous studies have demonstrated that 4F2HC gene expression is induced during normal T-cell activation and that the activity of the gene is regulated, at least in part, by the interaction of a constitutively active 5'-flanking housekeeping promoter and a phorbol ester-responsive transcriptional attenuator element located in the exon 1-intron I region of the gene. We now report that 4F2HC intron 1 contains a transcriptional enhancer element which is active on a number of heterologous promoters in a variety of murine and human cells. This enhancer element has been mapped to a 187-base-pair RsaI-AluI fragment from 4F2HC intron 1. DNase I footprinting and gel mobility shift analyses demonstrated that this fragment contains two nuclear protein-binding sites (NF-4FA and NF-4FB) which flank a consensus binding site for the inducible AP-I transcription factor. Deletion analysis showed that the NF-4FA, NF-4FB, and AP-1 sequences are each necessary for full enhancer activity. Murine 4F2HC intron I displayed enhancer activity similar to that of its human counterpart. Comparison of the sequences of human and murine 4F2HC intron ls demonstrated that the NF-4FA, NF-4FB, and AP-1 sequence motifs have been highly conserved during mammalian evolution.
Antigen recognition by the heterodimeric a-13 receptor of human T lymphocytes (TCR a-1) results in a complex and precisely orchestrated set of changes in T-cell gene expression, including induction of a set of nuclear proto-oncogenes (19, 33) , production of a variety of soluble lymphokines (34) , and expression of a novel group of cell surface antigens (9) . While a great deal has recently been learned about the structural requirements for antigen recognition by the TCR (x-I molecule (for a review, see reference 11), less is understood about the molecular mechanisms involved in modulating inducible gene expression during T-cell activation. Cross-linking of the TCR ot-r-CD3 complex has been shown to result in phosphoinositol turnover, protein kinase C activation, and transient increases in cytosolic ionized calcium levels (for a review, see reference 1). How these and other second messengers subsequently regulate T-cell gene expression remains unclear.
We have utilized the 4F2 cell-surface antigen as a model system of gene regulation during human T-cell activation. 4F2 is a 120-kilodalton disulfide-linked heterodimer composed of an 85-kilodalton glycosylated heavy chain (4F2HC) and a 35-kilodalton nonglycosylated light chain (4F2LC) (18) . 4F2 is of interest in studies of T-cell activation because it is a T-cell activation antigen which is expressed at low levels on resting peripheral blood T cells and is rapidly induced after activation with lectins or antigen (9) . Increases in cell surface expression of 4F2 first occur 4 h after lectin stimulation and peak at 16 to 20 h, before the onset of DNA synthesis or the appearance of the 55-kilodalton interleukin-2 receptor ax chain (9) . In addition, monoclonal antibodies to 4F2HC are able to block the proliferation of cultures of Corresponding author. activated T cells in vitro (10) , suggesting that 4F2 is intimately involved in T-cell activation.
The 1.9-kilobase (kb) 4F2HC cDNA encodes a 529-aminoacid type II membrane glycoprotein (32, 39) . 4F2HC is encoded by a single-copy human (and murine) gene and does not display significant homology with other known proteins (28a, 32, 39) . Our previous studies demonstrated that 4F2HC gene expression is induced 60-fold during normal T-cell activation and that the gene can be activated by both the phorbol ester-inducible protein kinase C pathway and the ionomycin-inducible calcium-mediated activation pathway (16, 25) . Studies of the structure of the 4F2HC gene and the molecular mechanisms responsible for 4F2HC gene regulation in resting and activated T cells demonstrated that the gene contains a G+C-rich 5'-flanking housekeeping promoter which lacks TATA and CCAAT sequences but contains binding sites for the ubiquitous Spl transcription factor (16) . This promoter is equally active in resting and phorbol ester-activated human peripheral blood T cells (25) . The low steady-state levels of mature 4F2HC mRNA found in resting T cells were shown to be the result of a block to transcription elongation within the exon 1-intron 1 region of the gene. Phorbol ester activation removes this block to transcription elongation, resulting in increased levels of full-length 4F2HC mRNA (25) .
To map the sequences responsible for transcriptional attenuation in the 4F2HC gene, 4F2HC 5'-flanking, exon 1, and intron 1 sequences were introduced into plasmid pSV2CAT (15) Plasmids and synthetic oligonucleotides. The plasmids pSV2CAT (15) , pUTKAT1 (30) , p4F2CAT (16) (containing the human 4F2HC promoter cloned into the HindIII site of pSVOCAT [15] ), and pSPCAT (24) have been described previously. The plasmid pSV2-I1CAT was constructed by cloning the 500-bp Stul-SacI human 4F2HC genomic fragment (16) (containing the entire 4F2HC intron 1 with small amounts of exon 1 and exon 2 sequences) in a 5' to 3' orientation into the HindIII site between the SV40 promoterenhancer and the bacterial CAT gene in pSV2CAT. Plasmids pSV2-I1Bam/CAT and pSV2-RI1Bam/CAT were constructed by cloning this same 500-bp fragment in both orientations into the BarnHI site located 3' of the CAT gene in pSV2CAT. Plasmids pUTKAT1-11 and pUTKAT1-RI1 were constructed by cloning the same 500-bp Stul-Sacl 4F2HC genomic fragment in both orientations into the BamHI site located 5' of the HSVTK promoter in pUTKAT1. Plasmid p4F2-I1Bam/CAT was constructed by cloning the same 4F2HC genomic fragment into the Ba,nHI site located 3' of the CAT gene in p4F2CAT. Plasmid pSPI1CAT was constructed by cloning the same 4F2HC genomic fragment into the SinaI site located 5' of the minimal SV40 promoter in pSPCAT (24) (see Fig. 1 for schematic representations of these plasmids). The 159-bp XhoII-NatrI, 129-bp HaeII, 213-bp KpnI-NarI, and 187-bp RsaI-AluI fragments from human 4F2HC intron 1 were cloned into the BarnHI site of pSV2CAT to create the pSV2-Xho/Nar cat, pSV2-Hae cat, pSV2-H3/Nar cat, and pSV2-Alu/Rsa cat plasmids (see Fig. 4 ).
Plasmids pSV2 NF4FA-cat, pSV2 NF4FB-cat, and pSV2
APl-cat were created by deleting the NF-4FA-, NF-4FB-, and AP-1-binding sites from the pSV2-Alu/Rsa cat plasmid with gapped heteroduplex, oligonucleotide-mediated, sitedirected mutagenesis (20) involving the following oligonucleotides: NF-4FA-, CATTGTCCTTCCCTCAAGCCGACC CGCCCC; NF-4FB-, GCGGCGCCAGAAGCCATGAAGT AATGTGCAGGACT; and AP-1-, CGTCACGAGGGTGG GGTCCTCCTTCCCCGC. The sequence of each of the mutants was confirmed by the dideoxy method (35) directly from the double-stranded plasmids with a synthetic oligonucleotide primer located 3' of the BamHI site in pSV2CAT (GTTTGTCCAAACTCATC). All oligonucleotides were synthesized on an Applied Biosystems model 380B DNA synthesizer.
CAT assays. All cell lines were transfected, by the DEAEdextran method as previously described (16) , with 10 ,ug of the appropriate plasmids purified by banding in CsCl. In some experiments, transfection frequencies were monitored by cotransfection with 2 pg of plasmid pRSVGH, a derivative of the previously described plasmid pOGH (37) , which contains the Rous sarcoma virus long terminal repeat driving transcription of the human growth hormone gene. Cell extracts were prepared 48 h after transfection by four cycles of freeze-thawing, and protein content was determined by a commercially available assay (Bio-Rad Laboratories, Richmond, Calif.). CAT assays were performed on cell extracts normalized for protein content by using standard techniques and ascending thin-layer chromatography (TLC) as previously described (16) . All experiments were repeated at least three times to ensure reproducibility of both the transfections and the CAT assays. In some experiments, in order to equalize for differences in transfection efficiencies, growth hormone levels were determined from the same extracts used for CAT assays with a commercially available kit (Nichols Institute Diagnostics, San Juan Capistrano, Calif.). After autoradiography, spots were cut from the TLC plates and counted in a liquid scintillation counter.
DNase I footprinting. Nuclear extracts were prepared from exponentially growing Jurkat cells as described by Dignam et al. (12) polyacrylamide-6 M urea sequencing gels. Standard MaxamGilbert purine-sequencing reaction mixtures (26) were prepared and electrophoresed adjacent to the footprinting reactions in each experiment.
Gel mobility shift assays. Gel mobility shift assays were performed as described by Singh et al. (38) [pH 8.5 ]) run at 100 V for 2 to 3 h. Gels were dried and subjected to autoradiography with intensifying screens (Du Pont Co., Wilmington, Del.). For cold competition experiments, binding reactions took place in the presence of 10 to 50 ng of cold competitor double-stranded oligonucleotide.
Cloning and sequencing of murine 4F2HC intron 1. A murine 4F2HC genomic clone was identified by hybridization of 106 recombinant clones from a murine genomic library (Clonetec, Palo Alto, Calif.) to a radiolabeled murine 4F2HC cDNA (28a). A 1.35-kilobase BamnHI restriction enzyme fragment from this genomic 4F2HC clone which contained intron 1 was identified by hybridization to a synthetic oligonucleotide probe (ATCGGCGACCTTCA GGC) homologous to the 3' end of the 4F2HC exon 1 sequence (the position of which was determined from the human 4F2HC genomic structure [16] ) and subcloned into pUC18. Murine 4F2HC intron 1 was sequenced directly from double-stranded DNA by using the dideoxy-chain termination method (35) and synthetic oligonucleotide primers corresponding to the 3' end of murine 4F2HC exon 1 (ATCGGC GACCTTCAGGC) and the 5' end of murine 4F2HC exon 2 (GCCCTTCACCTTCAGGG) as well as to a sequence from the middle of the intron (GGGTGCCTGACTCAGCA and TGCTGAGTCAGGCACCC) determined by using the exon primers as described above. The entire intron (including the intron-exon boundaries) was sequenced on both strands. The human and murine intron 1 sequences were compared by using the ALIGN program of the DNASTAR software package (DNASTAR, Madison, Wis.).
RESULTS
4F2HC intron 1 contains a transcriptional enhancer element. In an attempt to map the sequences responsible for the previously reported (25) transcriptional attenuator activity of the 4F2HC gene exon 1-intron 1 region, a genomic fragment containing 4F2HC intron 1 was subcloned into the HindIll site of plasmid pSV2CAT (15) between the SV40 promoterenhancer and the bacterial CAT reporter gene (Fig. 1A ). This construct, along with the control plasmid pSV2CAT, was transfected into human Jurkat T cells by using DEAEdextran (16) , and transcriptional activity was monitored by CAT assay (Fig. 1A) . The SV40 promoter-enhancer was relatively inactive in Jurkat cells, as evidenced by the low CAT activity produced by transfection of the control plasmid pSV2CAT. Surprisingly, plasmid pSV2-I1CAT, containing the 500-bp 4F2HC genomic fragment which includes the entire 4F2HC intron 1 surrounded by short regions of exon 1 and exon 2 sequences to allow for accurate splicing (Fig. 1A , pSV2-I1CAT), displayed CAT activity 60-fold higher than that of plasmid pSV2CAT alone (Fig. 1A ). To determine whether this effect was due to an enhancer element or to a cryptic promoter within this region of the 4F2HC gene, the same fragment was subcloned in both orientations into the BamHI site which lies 3' of the bacterial CAT gene in pSV2CAT (Fig. 1A , pSV2-I1Bam/CAT and pSV2-RI1Bam/ CAT). Both constructs expressed 40 to 45 times more CAT activity than did control plasmid pSV2CAT (Fig. 1A) , indicating that this fragment contains a potent transcriptional enhancer element. To determine whether the 4F2HC enhancer required the presence of the SV40 enhancer element or was active on the minimal SV40 promoter, the 500-bp 4F2HC intron 1 fragment was cloned 5' of the minimal SV40 promoter in plasmid pSPCAT (24) and transfected into Jurkat cells (Fig. 1A) . pSPI1CAT containing the 4F2HC intron 1 fragment expressed 35 times more CAT activity than did the control plasmid pSPCAT, indicating that the 4F2HC enhancer was active on the minimal SV40 promoter in the Jurkat cells. In a parallel series of experiments, 4F2HC intron 1 was also shown to enhance transcription from both the 4F2HC and HSVTK promoters, resulting in 5-to 10-fold increases in the activity of these promoters in Jurkat cells (Fig. 1B and C) .
To determine the cellular specificity of this enhancer, pSPCAT and pSPI1CAT were used to transfect a variety of human cell lines, including K562 erythroleukemia cells, clone 13 B cells, and HeLa fibroblasts. In all cases, 4F2HC intron 1 was able to increase transcription from the minimal SV40 promoter by 5-to 30-fold (Fig. 2) . In addition, human 4F2HC intron 1 was also able to significantly increase transcription from the minimal SV40 promoter in murine EL4 T cells and L-cell fibroblasts (data not shown). Together, these results indicated that intron 1 of the 4F2HC gene contains a transcriptional enhancer element which can function with a number of heterologous promoters in an orientation-and position-independent fashion in a wide variety of cell types. The potency of this enhancer in T cells is remarkable; it is able to significantly increase transcription from the SV40 promoter even in the presence of the SV40 enhancer element (Fig. 1A) .
Mapping the 4F2HC enhancer. To more precisely map the 4F2HC enhancer element, a variety of restriction enzyme fragments from 4F2HC intron 1 were subcloned into the BarnHI site 3' of the bacterial CAT gene in pSV2CAT and assayed for their ability to enhance CAT transcription in Jurkat cells (Fig. 3) . Fragments from the 5' half of the intron (bp 81 to 240; pSV2-Xho/Nar cat) or the 3' half of the intron (bp 243 to 372; pSV2-Hae cat) produced by digestion with XhoII-NarI or HaeII displayed a marked reduction in enhancer function, although both fragments retained the ability to enhance CAT expression by 10-to 15 -fold compared with the control plasmid pSV2-cat. In contrast, the 187-bp AluIRsaI fragment from the middle of the intron (bp 110 to 297; pSV2-Alu/Rsa cat) displayed full enhancer activity (Fig. 3) .
These results demonstrated that while all the enhancer sequences map to a relatively small fragment from the center of the intron, sequences on both sides of the NarI site (bp 240) are needed for full enhancer activity. Thus, either the NarI site lies in the middle of a single enhancer motif or there are multiple enhancer motifs which flank this site.
The 4F2HC enhancer contains two novel nuclear proteinbinding sites which flank a consensus binding site for the AP-1 transcription factor. A number of viral and cellular transcriptional enhancer elements have been shown to contain specific binding sites for nuclear transcriptional regulatory proteins (for reviews, see references 14, 27, and 31). To identify putative 4F2HC enhancer nuclear protein-binding sites, restriction enzyme fragments from 4F2HC intron 1 were subjected to DNaseI footprint analyses by using nuclear extracts prepared from Jurkat T cells (Fig. 4) . Two sequence motifs (NF-4FA and NF-4FB) within the AluI-RsaI enhancer fragment were specifically protected by Jurkat nuclear proteins. These sites were protected on both strands.
In addition to the NF-4FA and NF-4FB sites, an 18-bp sequence (NF-4FC) directly 5' of the AP-1 site was partially protected by Jurkat nuclear proteins (Fig. 4) .
Interestingly, the NF-4FA-and NF-4FB-binding sites surround a consensus binding site for the AP-1 transcription factor (3, 22) . While the AP-1 site was not protected by unstimulated Jurkat nuclear extracts, the DNase I cleavage pattern of the site was subtly altered in the presence of A. Plasmids pSPCAT and pSPI,CAT (upper panel) were used to transfect human Jurkat T cells, K562 erythroleukemia cells, clone 13 B cells, and HeLa fibroblasts, and CAT activities were determined from extracts normalized for protein content as described in Materials and Methods. The percent acetylation produced by each transfectant extract was determined after liquid scintillation counting of acetylated and unacetylated spots cut from the TLC plates. Relative enhancer activity was calculated as percent acetylation for pSPI1CAT divided by percent acetylation for pSPCAT. The values shown represent means for three separate transfections, at least one of which contained a cotransfected growth hormone plasmid to normalize for differences in transfection efficiencies.
Jurkat nuclear proteins (Fig. 4, arrows) . In addition, the NF-4FA-and NF-4FB-binding sites identified by DNaseI footprinting lie on either side of the NailI restriction enzyme site, which was shown above to bisect the enhancer elements present in the 4F2HC RsalI-AluI fragment (Fig. 3) .
To confirm the specificity of binding of the NF-4FA and NF-4FB proteins, synthetic oligonucleotides corresponding to the two binding sites were synthesized and used in gel mobility shift assays with Jurkat nuclear extracts (Fig. 5) . Jurkat nuclear extracts contained several proteins able to bind to the NF-4FA and NF-4FB oligonucleotides and shift their electrophoretic mobility. Cold competitor experiments demonstrated that formation of one of the shifted NF-4FA complexes (Fig. 5A, arrow) was inhibited in a dose-dependent manner by excess specific NF-4FA cold competitor oligonucleotide but not by an identical amount of cold NF-4FB competitor. Similarly, formation of one of the shifted NF-4FB complexes (Fig. SB, arrow) There are at least three distinct cis-acting sequences (NF-4FA, NF-4FB, and AP-1) within the 4F2HC enhancer which bind Jurkat nuclear proteins; each appears to be necessary for full enhancer activity. The importance of these sequences in determining enhancer activity is supported both by deletion experiments and by the finding that they have each been highly conserved during mammalian evolution. In addition, we have identified a fourth sequence, NF-4FC, which lies immediately 5' to the AP-1-binding site and which is less perfectly footprinted by Jurkat nuclear extracts and less highly conserved in mouse 4F2HC intron 1. The importance of the NF-4FC binding site in determining enhancer activity remains unclear. Of note, the locations of these nuclear protein-binding sites correspond to two previously described DNase I-hypersensitive sites located within intron 1 of the human 4F2HC gene in peripheral blood T-cell DNA (16) .
The finding of multiple cis-acting sequences, each of which is necessary for full 4F2HC enhancer function, is reminiscent of the results of previous studies of the SV40 (8, 13, 28) and immunoglobulin heavy-chain (23, 29) transcriptional enhancers, both of which contain multiple nuclear protein-binding sites which are necessary for full activity. The finding that deletion of the NF-4FA-, NF-4FB-, or AP-1-binding site results in the loss of the majority of enhancer activity suggests that the three binding sites or their cognate nuclear proteins may interact to activate the 4F2HC enhancer. However, it remains possible that deletion of one or more of these sites decreases enhancer activity by altering the geometry of the enhancer rather than by abolishing the binding of its nuclear proteins. These models are being tested by constructing CAT vectors containing various combinations of synthetic oligonucleotides corresponding to each of the 4F2HC enhancer nuclear protein-binding sites.
To our knowledge the NF-4FA and NF-4FB sequences are distinct from previously described enhancer motifs. In contrast, the AP-lIc-jun gene product (2, 6) (and its cognate sequence) has previously been shown to be responsible for the phorbol ester inducibility of a number of genes (3, 22) , including the human metallothionein "A gene and the collagenase gene (40) . Given our previous finding that the 4F2HC gene is induced by phorbol ester treatment of resting T cells (25) and that this induction is mediated by the removal of a block to transcription elongation within the exon 1-intron 1 region of the gene, it was particularly interesting to identify a consensus binding site for the AP-1 transcription factor within the 4F2HC intron 1 enhancer. Despite our inability to reproducibly footprint the AP-1-binding site with unfractionated Jurkat nuclear extracts, the importance of this site in determining enhancer activity was demonstrated by the finding that its deletion resulted in significant decreases in enhancer activity. However, it remains unclear whether the AP-1 site is also involved in the activation of 4F2HC gene expression during phorbol ester treatment of resting peripheral blood T cells. Although phorbol ester treatment of murine fibroblasts was recently shown to result in induction of the AP-1/c-juin gene (21) , the effect of phorbol ester B VOL. 9, 1989 .S) Together with our previous studies (16. 25) . the results presented in this report demonstraite that 4F2HC gene expression is highly regulated by a unique combination of molecular mechanisms which include (i) a 5'-flanking, constitutively active promoter which contains a calcium-responsive element; (ii) a block to transcription elongation within the exon 1-intron 1 region of the gene which can be modulated by phorbol ester treatment; and (iii) a potent transcriptional enhancer element which is contained in a 187-bp fragment from intron 1 of the gene (Fig. 8) . While several other genes have been shown to be regulated by transcriptional attenuation or to have intronic transcriptional enhancer elements, to our knowledge the 4F2HC gene is the first example of a gene which combines these two regulatory elements. It is tempting to speculate on the functional relation of the 4F2HC transcriptional attenuator and enhancer elements. Preliminary analyses indicate that the sequences responsible for transcriptional attenuation of 4F2HC gene transcription may map to the 5' end of exon 1 (data not shown). It is possible that inactivity of the 4F2HC enhancer in resting T cells results in an increased probability of premature transcription termination, possibly due to an exon 1 sequence element which is difficult for the RNA polymerase ll complex to traverse. T-cell activation (via the protein kinase C pathway) might result in enhancer activation, which, in turn, might stabilize the RNA polymerase complex, resulting in transcriptional read-through and increased levels of mature 4F2HC mRNA. Alternatively, it remains possible that attenuator and enhancer activity are (Fig. 3) by oligonucleotide-mediated. site-directed mutagenesis to yield pSV2 NF4FA-cat. pSV2 NF4FB-cat. and pSV2 APl-cat. respectively. These plasmids, along with the control plasmids pSV2-cat and pSV2-Alu/Rsa cat, were transfected into Jurkat cells, and CAT activity was determined as described in Materials and Methods. CAT activities for each transfection were compared with that for the pSV2-cat plasmid transfection. which was normalized to a value of 1. The pSV2-cat plasmid is identical to the pSV2CAT plasmid shown in lOv  20v  30v  40v  50v  60v  70v  H4F2I1 GTGAGTGCAGCGCGCCCCCGT T C TC   AGGGTG TGACTCOGOC  CTCCT CCC  GCG GC0  AGCCAGTT  M4F2I1  TTCTTCCTAAGGGTG CTGACTC OCACATCATCTTTCTCCTCTCCCCTCCCCCAACCACGCG--GCO CTGAGCCAGTTC   210A   220^230^240^250^260^270^2802   60v  270v  280v  290v  300v  310v  320v  330v  H4F21C1ACCGGTTTGCTAATGTGCAGGACTCCTTACATCAGCTCCTCTGAGTCTCGTGATTCAGCCTTGCCTCCCTCTCT AACC GTTTCT GTAATGTG 290A   300^310A   3203  40v  350v  360v  370v  380v  390v  400v   H4F2I1  CCCCCTTTGCCCCCTCCCCGTCCCACCCTTAGGCGCT ---GGGAGAAGGGA-GG -CT00-CGGAGGTCAGGGG   CTTTG  CTC  TCC ACCC  GCG  GGGAG GGGA  GGTGG   GGAGG  G GG   M4F2I 1   ----CTTTGT ---CTCATGATCCAACCC ----GCGTCGAGAGGGAGTCGGGAAGTGGTGGAGOAAATGTGGAGGCTGGAGG   330^340^350^360^370^380A  3904  10v  420v  430v  440v  450v  460v  470v   H4F211  CCTCTCAGAGGGGCCTCACTTGTTAACCCAGCCCCCATTTC --AAGGTCTGAAGGGGCGTCTCGATTACCTG   C T TCA  GCC A T GTTAACCCA CCC C  TC AGGTCTGAAG G C TCT GA TAC TG  M4F2I1 CTTTTCAT -----GCCCTATTGGTTAACCCAACCCTCTCCTCCTAGGTCTGAAGACCATCTGGAGTACTTG mediated by the interaction of distinct sets of tralns-acting factors with a single set of intron 1 cis-acting sequences.
In testing these models, it will be of interest to determine whether there are differences in the DNA-binding activities or mRNA levels of the NF-4FA, NF-4FB, and AP-1Icjiun gene products in activated versus resting T cells. In addition, because T-cell activation has been shown to increase c-Jo)s mRNA levels (17, 33) and because the c-fos gene product was recently shown to associate with and activate the AP-1 transcription factor (7, 36) , it is possible that de novo c-fos transcription and translation are necessary for 4F2HC enhancer activation. This hypothesis is in accord with our previous finding of a requirement for protein synthesis in 4F2HC gene activation in T cells (25) . Finally, it will be of interest to determine whether the c-mvc and c-mnvb protooncogenes which have recently been reported to be regulated by transcriptional attenuation (4, 5) also contain intragenic enhancer elements, i.e., whether transcriptional attenuators are commonly associated with or regulated by intragenic transcriptional enhancers. While further studies will be needed to precisely identify the role of the 4F2HC enhancer element in regulating 4F2HC gene expression, the identification and characterization of this enhancer should facilitate future experiments designed to better understand the biochemical pathways involved in regulating inducible gene expression during T-cell activation.
